- Home
- BRLT vs TENX Comparison
BRLT vs TENX Comparison
Compare BRLT & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRLT
- TENX
- Stock Information
- Founded
- BRLT 2005
- TENX 1967
- Country
- BRLT United States
- TENX United States
- Employees
- BRLT N/A
- TENX N/A
- Industry
- BRLT Consumer Specialties
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- BRLT Consumer Discretionary
- TENX Health Care
- Exchange
- BRLT Nasdaq
- TENX Nasdaq
- Market Cap
- BRLT 22.6M
- TENX 21.7M
- IPO Year
- BRLT 2021
- TENX N/A
- Fundamental
- Price
- BRLT $1.54
- TENX $6.42
- Analyst Decision
- BRLT Hold
- TENX Strong Buy
- Analyst Count
- BRLT 4
- TENX 3
- Target Price
- BRLT $2.20
- TENX $16.00
- AVG Volume (30 Days)
- BRLT 71.4K
- TENX 43.8K
- Earning Date
- BRLT 03-12-2025
- TENX 03-25-2025
- Dividend Yield
- BRLT N/A
- TENX N/A
- EPS Growth
- BRLT N/A
- TENX N/A
- EPS
- BRLT 0.03
- TENX N/A
- Revenue
- BRLT $422,161,000.00
- TENX N/A
- Revenue This Year
- BRLT $2.43
- TENX N/A
- Revenue Next Year
- BRLT $10.40
- TENX N/A
- P/E Ratio
- BRLT $49.87
- TENX N/A
- Revenue Growth
- BRLT N/A
- TENX N/A
- 52 Week Low
- BRLT $1.25
- TENX $2.77
- 52 Week High
- BRLT $3.02
- TENX $7.89
- Technical
- Relative Strength Index (RSI)
- BRLT 57.67
- TENX 49.83
- Support Level
- BRLT $1.54
- TENX $6.00
- Resistance Level
- BRLT $1.75
- TENX $6.76
- Average True Range (ATR)
- BRLT 0.13
- TENX 0.42
- MACD
- BRLT 0.03
- TENX 0.01
- Stochastic Oscillator
- BRLT 41.94
- TENX 40.37
About BRLT Brilliant Earth Group Inc.
Brilliant Earth Group Inc designs, procures and sells ethically-sourced diamonds, gemstones and jewelry online and through showrooms. Its sales consist of revenue from diamond, gemstone, and jewelry retail sales. The company sells its products in the U.S. and other international countries, of which a majority of revenue is derived from the U.S.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.